COVID-19 vaccine (mRNA BNT162b2) and COVID-19 infection-induced thrombotic thrombocytopenic purpura in adolescents

Pediatr Blood Cancer. 2022 Jun;69(6):e29681. doi: 10.1002/pbc.29681. Epub 2022 Apr 4.

Abstract

The mRNA COVID-19 vaccine and COVID-19 infection caused by the SARS-CoV-2 virus may be immunologic triggers for the development of thrombotic thrombocytopenic purpura (TTP). There is not yet literature that discusses TTP induced by COVID-19 vaccination or infection in pediatric or adolescent patients. We describe three adolescents presenting with TTP (both de novo and relapsed disease) following administration of the Pfizer COVID-19 vaccine or after COVID-19 infection. Our observations demonstrate that the Pfizer-BioNTech mRNA vaccine and COVID-19 infection can act as triggers for the development/relapse of both congenital and acquired TTP.

Keywords: COVID-19; TTP; acquired TTP; vaccination.

MeSH terms

  • Adolescent
  • BNT162 Vaccine
  • COVID-19 Vaccines / adverse effects
  • COVID-19* / complications
  • Child
  • Humans
  • Purpura, Thrombotic Thrombocytopenic* / genetics
  • RNA, Messenger / genetics
  • SARS-CoV-2
  • Vaccines, Synthetic
  • mRNA Vaccines

Substances

  • COVID-19 Vaccines
  • RNA, Messenger
  • Vaccines, Synthetic
  • mRNA Vaccines
  • BNT162 Vaccine